A timeline of the key events for the new Everton Stadium as the Blues' future home hosts its historic first game ...

Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...

BLBD remains volatile despite strong earnings, federal funding uncertainties, and revised EV sales guidance. Explore more ...

The company seems to have a tremendous opportunity ... a brief business description for those who don't know much about Blue Bird. The firm was founded in 1927 in Macon, Georgia, and it's ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital ...

Blue Bird Corporation (NASDAQ:BLBD), a leading manufacturer of school buses, has been making significant strides in the electric vehicle (EV) market while improving its operational efficiency.

StockNews.com raised shares of Blue Bird from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Needham & Company LLC reduced their price target on shares ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...